AVROBIO rises on positive data from investigational gene therapy trial

Tectonic Therapeutic

18/05/2023 13:02

** Shares of gene therapy developer AVROBIO Inc  AVRO.O 
rise ~12% premarket to 65 cents
    ** Co announces positive data from early to mid-stage trial
of its investigational gene therapy for cystinosis treatment 
    ** Cystinosis is a rare genetic condition that causes an
amino acid called cystine to accumulate in cells
    ** Co says data demonstrates a durable treatment effect
across key measures out to 36 months
    ** Follow-up data suggest that after receiving gene therapy,
patients can produce functional cystinosin protein throughout
the body - AVRO
    ** The fully enrolled trial is monitoring long-term safety
and efficacy in six adult patients affected by the most severe
and common form of cystinosis who previously had been treated
with the standard of care cysteamine
    ** Co said received positive regulatory feedback from US FDA
and UK's MHRA
    ** Up to last close, stock down ~19% YTD
    

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))